Fusion Pharmaceuticals Inc.
Healthcare · Biological Products, (No Diagnostic Substances) · Z4 · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|
| Revenue | $2.1M | $1.5M | $1.4M | — | — |
| Operating income | −$99.2M | −$88.0M | −$82.0M | −$37.9M | −$18.2M |
| Net income | −$94.9M | −$87.6M | −$81.0M | −$78.3M | −$16.2M |
| Total assets | $285.8M | $219.1M | $252.3M | $310.7M | $69.4M |
| Total liabilities | $63.4M | $56.8M | $20.8M | $16.2M | $10.3M |
| Equity | $222.5M | $162.2M | $231.5M | $294.5M | −$33.5M |
| EPS (diluted) | $-1.45 | $-2.00 | $-1.90 | — | — |
| Shares out. | 63.2M | 43.3M | 41.8M | 41.7M | 1.9M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2023- Operating margin
- −4798.5%
- Net margin
- −4588.8%
- Return on equity
- −42.7%
- Return on assets
- −33.2%
- Return on capital (ROCE)
- −36.8%
- Liabilities / assets
- 22.2%
- Debt / equity
- 0.28×
- Book value / share
- $3.52
- Revenue growth (YoY)
- 41.5%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2023- Altman Z″ (distress)
- 2.27grey zone
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 6/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 warning● 3 good- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Altman Z″ in the grey zone
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout first- Phase 2Active Not Recruitingreadout ~2025-05-30Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).
- Phase 2Active Not Recruitingreadout ~2026-12-23FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
- Phase 2Active Not Recruitingreadout ~2027-05FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Other material eventJun 4, 2024
- Other material eventMay 31, 2024
- Shareholder vote · Regulation FD disclosureMay 29, 2024
- Other material eventMay 10, 2024
- Results of operationsMay 7, 2024
- Other material eventMay 2, 2024
- Other material eventApr 23, 2024
- Other material eventApr 9, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.